Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T E Witzig

Showing results (111-120 of 183) with videos related to

Pageof 19
Sort By:
Mayo Clinic Proceedings|September 20, 2000
Thalidomide in the treatment of relapsed multiple myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myelomaS V Rajkumar, R Fonseca, M Q Lacy, et al.
Blood Cancer Journal|July 22, 2017
Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cellsN Shenoy, T Bhagat, E Nieves, et al.
Bone Marrow Transplantation|August 5, 2000
Delayed stem cell transplantation for the management of relapsed or refractory multiple myelomaM A Gertz, M Q Lacy, D J Inwards, et al.
Cancer|September 15, 1994
DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancerT E Witzig, J N Ingle, S S Cha, et al.
Blood|November 26, 1999
Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphomaC A Hanson, P J Kurtin, J A Katzmann, et al.
Leukemia|August 2, 2001
Thalidomide for previously untreated indolent or smoldering multiple myelomaS V Rajkumar, A Dispenzieri, R Fonseca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphomaD J Inwards, P A Fishkin, B R LaPlant, et al.
American Journal of Clinical Pathology|March 1, 1989
Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedureT E Witzig, N J Gonchoroff, P R Greipp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2014
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphomaD J Inwards, P A Fishkin, B R LaPlant, et al.
Pageof 19

Showing results (111-120 of 183) with videos related to

Sort By:
Pageof 19
Mayo Clinic Proceedings|September 20, 2000
Thalidomide in the treatment of relapsed multiple myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myelomaS V Rajkumar, R Fonseca, M Q Lacy, et al.
Blood Cancer Journal|July 22, 2017
Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cellsN Shenoy, T Bhagat, E Nieves, et al.
Bone Marrow Transplantation|August 5, 2000
Delayed stem cell transplantation for the management of relapsed or refractory multiple myelomaM A Gertz, M Q Lacy, D J Inwards, et al.
Cancer|September 15, 1994
DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancerT E Witzig, J N Ingle, S S Cha, et al.
Blood|November 26, 1999
Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphomaC A Hanson, P J Kurtin, J A Katzmann, et al.
Leukemia|August 2, 2001
Thalidomide for previously untreated indolent or smoldering multiple myelomaS V Rajkumar, A Dispenzieri, R Fonseca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphomaD J Inwards, P A Fishkin, B R LaPlant, et al.
American Journal of Clinical Pathology|March 1, 1989
Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedureT E Witzig, N J Gonchoroff, P R Greipp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2014
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphomaD J Inwards, P A Fishkin, B R LaPlant, et al.
Pageof 19